SCHEMBL6601710

SCHEMBL6601710

O=C(Nc1ccc(CO)cc1)c1c(Cl)cccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 6/20 0.61
JAK2 O60674 4/20 0.61
JAK1 P23458 4/20 0.61
CYP3A4 P08684 1/20 0.61
TAS1R3 Q7RTX0 1/20 0.60
TAS1R1 Q7RTX1 1/20 0.60
TAS1R2 Q8TE23 1/20 0.60
KMT2A Q03164 1/20 0.59
ITGB1 P05556 9/20 0.54
ITGA4 P13612 9/20 0.54
ITGA2 P17301 1/20 0.54
ITGB7 P26010 1/20 0.54
KLKB1 P03952 1/20 0.54
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063160 0.84 ITGB1 (0.64) TYK2JAK2JAK1CYP3A4ITGB1
SCHEMBL27796647 0.82 SMO (0.68) TYK2JAK2KMT2AKLKB1MAPT
SCHEMBL28097825 0.81 FFAR1 (0.57) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL4154853 0.80 TYK2 (0.71) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL14532180 0.79 TYK2 (0.65) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL95630 0.79 TYK2 (0.65) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL678659 0.79 KMT2A (0.67) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL7384072 0.79 TYK2 (0.65) TYK2JAK2JAK1CYP3A4TAS1R3
SCHEMBL5230799 0.78 ITGB1 (0.64) ITGB1ITGA4ITGA2ITGB7
SCHEMBL27515653 0.78 ITGB1 (0.64) ITGB1ITGA4ITGA2ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1066316-B1 CINNAMIC ACID DERIVATIVES HAVING CELL ADHESION MODULATING ACTIVITY CELLTECH THERAPEUTICS LTD (GB) 2004-05-12 EP disclosed
US-6329362-B1 MODULATION CELL ADHESION THE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. CELLTECH THERAPEUTICS LIMITED (GB) 2001-12-11 US disclosed